Advaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright

Advaxis, Inc. (NASDAQ:ADXS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday. They presently have a $23.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 378.17% from the stock’s previous close.

ADXS has been the topic of a number of other reports. BidaskClub lowered shares of Advaxis from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine lowered shares of Advaxis from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $19.00 price objective on shares of Advaxis in a report on Wednesday, May 31st.

Advaxis (NASDAQ:ADXS) opened at 4.81 on Friday. The firm has a 50-day moving average of $6.30 and a 200 day moving average of $7.42. Advaxis has a 12-month low of $4.77 and a 12-month high of $12.66. The stock’s market capitalization is $194.62 million.

Advaxis (NASDAQ:ADXS) last released its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%. On average, analysts predict that Advaxis will post ($2.20) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Advaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/09/17/advaxis-inc-adxs-rating-reiterated-by-hc-wainwright.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN raised its holdings in shares of Advaxis by 0.8% in the 1st quarter. Wells Fargo & Company MN now owns 43,669 shares of the biotechnology company’s stock valued at $356,000 after purchasing an additional 360 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Advaxis by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock valued at $840,000 after purchasing an additional 817 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Advaxis by 4.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the biotechnology company’s stock valued at $180,000 after purchasing an additional 1,000 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Advaxis by 2.9% in the 1st quarter. SG Americas Securities LLC now owns 49,333 shares of the biotechnology company’s stock valued at $403,000 after purchasing an additional 1,398 shares in the last quarter. Finally, American International Group Inc. raised its holdings in shares of Advaxis by 7.6% in the 1st quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 1,459 shares in the last quarter. Institutional investors and hedge funds own 48.78% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply